Annovis Bio Inc. (NYSE: ANVS), a Phase 3 clinical-stage biotechnology company focused on neurodegenerative diseases, announced it will host a corporate update webinar on September 2, 2026, at 4 p.m. EDT. The webinar will feature founder, President and CEO Maria Maccecchini, Ph.D., who will discuss recent progress, ongoing clinical programs, and upcoming milestones. This announcement comes as the company prepares for a pivotal year ahead, with top-line data from its fully enrolled Phase 3 Alzheimer’s disease (AD) trial and regulatory submissions expected in 2027.
The webinar will be followed by a live question-and-answer session, providing investors and stakeholders an opportunity to engage directly with management. Annovis is developing buntanetap, an investigational once-daily oral therapy designed to inhibit the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing these underlying causes of neurodegeneration, the company aims to halt disease progression and improve cognitive and motor functions in patients.
In addition to the Phase 3 AD trial, Annovis plans to begin enrolling patients in an AD open-label study in October 2026 to generate long-term safety data. The company’s Parkinson’s disease (PD) open-label study is already underway, and discussions continue regarding the initiation of a Parkinson’s disease dementia program. These initiatives underscore Annovis’s commitment to advancing its pipeline and addressing the urgent need for disease-modifying therapies in neurodegenerative diseases.
The announcement highlights the importance of the upcoming milestones for the company. The Phase 3 AD trial’s top-line data, expected in 2027, will be a critical readout for buntanetap’s efficacy and safety profile. Positive results could position buntanetap as a potential first-in-class treatment for Alzheimer’s disease, a market with significant unmet medical need. Similarly, progress in the PD program and the potential expansion into Parkinson’s disease dementia could broaden the drug’s therapeutic applications.
Investors and industry observers will be closely watching the webinar for details on trial progress, regulatory strategy, and any updates on the PD program. Annovis’s focus on multiple neurodegenerative indications reflects a strategic approach to maximize the potential of its platform. The company’s headquarters are in Malvern, Pennsylvania, and it continues to advance its clinical development efforts with a dedicated team.
For more information about the webinar and to access the full press release, visit https://ibn.fm/mls3F. Additional updates and news about Annovis Bio are available in the company’s newsroom at https://ibn.fm/ANVS.
